Search results
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via AOL· 7 hours agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 6 days agoOn Friday, Wells Fargo adjusted its outlook on shares of pharmaceutical giant Merck & Co., Inc....
Cerevance receives milestone payment under Alzheimer's collaboration with Merck
Seeking Alpha· 10 hours agoPrivately held Cerevance receives milestone payment from Merck for Alzheimer's research...
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 1 day agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Merck reports data from Phase III gastric cancer treatment trial
Clinical Trials Arena via Yahoo Finance· 18 hours agoMerck (MSD) has announced the final analysis findings from the Phase III KEYNOTE-811 clinical trial...
Merck KGaA's Dividend Analysis
GuruFocus.com via Yahoo Finance· 4 days agoMerck KGaA (MKKGY) recently announced a dividend of $0.47 per share, payable on 2024-05-09, with the ex-dividend date set for 2024-04-29. As investors...
Is Merck Stock Fully Valued At $130?
Forbes· 2 days agoMerck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates. The growth was primarily driven by higher sales...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Cantor Fitzgerald Brokers Boost Earnings Estimates for Merck & Co., Inc. (NYSE:MRK)
ETF DAILY NEWS· 3 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 3 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...